Ratiopharm in Sweden: Exploiting Electronics

Increasingly competitive generics markets are forcing companies to be as creative as they can in securing even a few weeks' head-start over competitors. Ratiopharm is exploiting Swedish GPs' widespread use of electronic prescription systems to circumnavigate a timing quirk in the country's substitution law and gain vital market share for its generic omeprazole.

October 2002 brought good news for Swedish generics firms—the advent of a generic substitution list. Even though Sweden, as a relatively high priced market, offers ample opportunities for generics companies to undercut branded manufacturers, penetration there has remained relatively low because only doctors could substitute a generic for a branded drug. That didn't happen very much because doctors had no direct incentive to do so. But now pharmacists can automatically fill branded prescriptions with a cheaper equivalent from the substitution list unless the doctor explicitly forbids it, just as recently became the case in Germany. (See "Generics in Germany: Aut idem Outrage," In Vivo Europe Rx, July/August 2002 [A#2002600021].)

But the new process has its glitches. A generics company first seeks approval for a product from the Swedish Medical Products Agency (MPA), then it goes to the pricing and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By 

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.